Asp Isotopes INC 8-K filings

ASP Isotopes Inc. has obtained all necessary regulatory approvals for its proposed acquisition of Renergen Limited, making the scheme of arrangement unconditional.

ASP Isotopes Inc. announces Paul Mann will resume his role as CEO and Executive Chairman, with Robert Ainscow continuing as Chief Operating Officer, effective January 19, 2026.

ASP Isotopes Inc. announced that founder and Executive Chairman Paul Mann will resume his role as Chief Executive Officer effective January 19, 2026, following a temporary health-related leave.

ASP Isotopes Inc. and Renergen Limited have mutually agreed to extend the longstop date for their proposed acquisition and a related term loan repayment to January 30, 2026, to secure remaining regulatory approvals.

ASP Isotopes Inc. filed an 8-K announcing the release of its Third Quarter Update Call presentation.

ASP Isotopes Inc. announced it will host a quarterly business update conference call and webcast on November 21, 2025, to discuss its operations and strategic initiatives.

ASP Isotopes Inc.'s wholly-owned subsidiary, Quantum Leap Energy LLC, has entered into an agreement to raise approximately $64.3 million through convertible promissory notes to fund laser enrichment facilities.

ASP Isotopes Inc.'s wholly-owned subsidiary, Quantum Leap Energy LLC (QLE), has confidentially submitted a draft registration statement for a proposed initial public offering of its Class A common stock.

Quantum Leap Energy LLC, a subsidiary of ASP Isotopes Inc., announced an initial closing of a $64.3 million private placement of convertible notes to fund laser enrichment facilities.

ASP Isotopes' UK subsidiary, Quantum Leap Energy Ltd., has initiated early engagement with UK nuclear regulators for the production of High-Assay Low Enriched Uranium (HALEU).

ASP Isotopes' subsidiary, Quantum Leap Energy, has acquired assets from One 30 Seven Inc. to develop advanced solutions for processing water-soluble nuclear waste.

ASP Isotopes Inc. announced the pricing of an underwritten public offering of 17.17 million shares of common stock, aiming to raise approximately $210.3 million.

ASP Isotopes Inc. announced a major silicon-28 supply agreement and the strategic acquisition of a U.S. radiopharmacy, expanding its global footprint in advanced materials and nuclear medicine.

ASP Isotopes Inc. announced that CEO Paul Mann is taking a temporary leave for health reasons, with COO Robert Ainscow appointed Interim CEO.

ASP Isotopes Inc. announced a purchase order for enriched Barium-137 from a U.S.-based customer, slated for Q1 2026 delivery, highlighting its role in scalable quantum computing.

ASP Isotopes Inc. announced executive management changes, appointing an Interim CEO as Paul Mann transitions to Executive Chairman due to health reasons, and a new CFO for its subsidiary Quantum Leap Energy LLC.

ASP Isotopes Inc.'s subsidiary, Quantum Leap Energy LLC, has acquired a controlling 79.14% voting interest in Skyline Builders Group Holding Limited to pursue critical materials supply chain opportunities.

ASP Isotopes Inc. has extended the longstop date for its acquisition of Renergen Limited to November 28, 2025, to secure remaining regulatory approvals and third-party consents.

ASP Isotopes Inc. strengthens its Board of Directors with the appointment of Ralph L. Hunter, a seasoned expert in nuclear power generation and clean energy.

ASP Isotopes Inc. announced the successful shipment of first samples of Ytterbium-176 and Silicon-28 to customers, projecting $50 to $70 million in potential revenues from these isotopes in 2026 and 2027.

ASP Isotopes Inc. announced a secondary listing on the JSE, progress in commercial production of Silicon-28 and Ytterbium-176, and a pivot to Carbon-12 enrichment.

ASP Isotopes Inc. and its subsidiary Quantum Leap Energy LLC have formed a joint venture with Fermi America to develop an advanced nuclear fuel research and production facility at the 11GW HyperGrid Campus in Texas.

ASP Isotopes Inc. announced the expected commencement of its dual listing on the Johannesburg Stock Exchange and provided an update on its acquisition of Renergen Limited.

ASP Isotopes Inc. has strategically invested $5 million in IsoBio, Inc., a radiotherapeutic development company focused on novel cancer therapies, securing a board seat and significant protective rights.

ASP Isotopes Inc. has invested $5 million in IsoBio, Inc.'s initial Series Seed funding round to accelerate the development of innovative Antibody-Isotope Conjugates (AICs™) for cancer treatment, leveraging ASPI's isotope manufacturing capabilities.

ASP Isotopes Inc. has received conditional approval from the Competition Commission of South Africa for its proposed acquisition of Renergen Limited, a key step towards creating a global leader in critical materials.

ASP Isotopes Inc. announced the pricing of a $60 million underwritten registered direct offering of 7.5 million common shares at $8.00 per share to a single institutional investor, providing significant capital for general corporate purposes.

An advanced materials company announces significant progress in isotope production, exceeding previous capacity guidance for Silicon-28 and advancing other key enrichment projects.

ASP Isotopes Inc. announced that Renergen Limited shareholders overwhelmingly approved its proposed acquisition, a strategic move expected to create a global leader in critical and strategically important materials.

ASP Isotopes Inc. announced the appointment of Dr. Ryno Pretorius as Chief Executive Officer of its subsidiary, Quantum Leap Energy LLC, to spearhead the development and commercialization of advanced nuclear fuels like HALEU and Lithium-6.